Search

Your search keyword '"P. Capovilla"' showing total 7 results
Start Over Author "P. Capovilla" Journal european journal of surgical oncology
7 results on '"P. Capovilla"'

1. Minimally invasive Ivor Lewis Esophagectomy in the elderly patient: a multicenter retrospective matched-cohort study.

Author

Scarton, Alessia, Capovilla, Giovanni, Uzun, Eren, Riccio, Federica, Sciuto, Maria Elisa, Moletta, Lucia, Hadzijusufovic, Edin, Provenzano, Luca, Salvador, Renato, Pierobon, Elisa Sefora, Tagkalos, Evangelos, Berthl, Felix, Lang, Hauke, Valmasoni, Michele, and Grimminger, Peter P.

Subjects
OLDER patients, ESOPHAGECTOMY, RETROSPECTIVE studies
Published
2024
Full Text
View/download PDF

2. Major Pathologic Response in Esophageal Adenocarcinoma: should we adopt a new paradigm in defining response to treatments?

Author

Scarton, Alessia, Sciuto, Maria Elisa, Capovilla, Giovanni, Riccio, Federica, Tagkalos, Evangelos, Uzun, Eren, Moletta, Lucia, Hadzijusufovic, Edin, Provenzano, Luca, Salvador, Renato, Pierobon, Elisa Sefora, Zanchettin, Gianpietro, Berthl, Felix, Lang, Hauke, Grimminger, Peter P., and Valmasoni, Michele

Subjects
ADENOCARCINOMA, THERAPEUTICS
Published
2024
Full Text
View/download PDF

3. The impact of pathological tumor response following neoadjuvant chemotherapy and chemoradiotherapy for esophageal adenocarcinoma. A retrospective multicenter cohort study.

Author

Scarton, Alessia, Capovilla, Giovanni, Riccio, Federica, Sciuto, Maria Elisa, Tagkalos, Evangelos, Eren, Uzun, Moletta, Lucia, Hadzijusufovic, Edin, Provenzano, Luca, Salvador, Renato, Pierobon, Elisa Sefora, Zanchettin, Gianpietro, Berthl, Felix, Lang, Hauke, Grimminger, Peter P., and Valmasoni, Michele

Subjects
NEOADJUVANT chemotherapy, CHEMORADIOTHERAPY, COHORT analysis, ADENOCARCINOMA, TUMORS, RECTAL cancer, ESOPHAGEAL cancer
Published
2024
Full Text
View/download PDF

4. Esophagogastric junction Siewert type II tumors, a challenge for the surgeon: comparison of results of transhiatal extended gastrectomy vs. Ivor Lewis Esophagectomy in a high-volume center.

Author

Pierobon, Elisa Sefora, Riccio, Federica, Sciuto, Maria Elisa, Scarton, Alessia, De Pasqual, Anna Laura, Nezi, Giulia, Moletta, Lucia, Zanchettin, Gianpietro, Capovilla, Giovanni, Salvador, Renato, Provenzano, Luca, and Valmasoni, Michele

Subjects
ESOPHAGOGASTRIC junction, ESOPHAGECTOMY, GASTRECTOMY, SURGEONS, TUMORS
Published
2024
Full Text
View/download PDF

7. Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study.

Author

Colpart, P., Monnien, F., Valmary-Degano, S., Ben Rejeb, H., Dartigues, P., Hommell-Fontaine, J., Isaac, S., Gilly, F.-N., Villeneuve, L., M'Hamdi, L., Mery, E., Lang Averous, G., Capovilla, M., Bibeau, F., Laverriere, M.-H., and Verriele-Beurrier, V.

Subjects
PROGRAMMED cell death 1 receptors, MESOTHELIOMA, IMMUNOHISTOCHEMISTRY, GENE expression, COMPANION diagnostics, BIOMARKERS, PROGNOSIS
Abstract

Background Epithelioid peritoneal malignant mesothelioma (EPMM) is the most common subtype of this aggressive tumor. We compared two antibodies against PD-L1, a recent theranostic biomarker, and evaluated the prognostic value of PD-L1 expression by mesothelial and immune cells in EPMM. Methods Immunohistochemistry was performed on 45 EPMM. Clinical and pathological data were extracted from the RENAPE database. Using E1L3N and SP142 clones, inter-observer agreement, PD-L1 expression by mesothelial and immune cells and inter-antibody agreement were evaluated. The prognostic relevance of PD-L1 expression was evaluated in 39 EPMM by univariate and multivariate analysis of overall survival (OS) and progression-free survival (PFS). Results Inter-observer agreement on E1L3N immunostaining was moderate for mesothelial and immune cells, and fair for mesothelial and poor for immune cells using SP142. Using E1L3N, 31.1% of mesothelial and 15.6% of immune cells expressed PD-L1, and 22.2% of mesothelial and 26.7% of immune cells using SP142. Inter-antibody agreement was moderate. In most positive cases, 1–5% of tumor cells were positive. Using E1L3N, PD-L1 expression by lymphocytes was associated with better OS and PFS by both univariate and multivariate analysis. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy predicted better prognosis than other treatments. Solid subtype was an independent prognostic factor for worse OS. Conclusion E1L3N appeared easier to use than SP142 to evaluate PD-L1 expression. A minority of EPMM expressed PD-L1, and only a few cells were positive. PD-L1 expression by immune cells evaluated with E1L3N was an independent prognostic factor in EPMM. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results